RT Journal Article
SR Electronic
T1 Rivaroxaban for treatment of venous thromboembolism. A real-life perspective in 103 patients
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P2396
VO 44
IS Suppl 58
A1 Raquel Sanchez-Oro-Gomez
A1 Luis Jara-Palomares
A1 Raquel Morillo-Guerrero
A1 Teresa Elias-Hernandez
A1 Marta Ferrer-Galvan
A1 Maribel Asensio-Cruz
A1 Remedios Otero-Candelera
YR 2014
UL http://erj.ersjournals.com/content/44/Suppl_58/P2396.abstract
AB Background: Rivaroxaban is an oral, active direct Factor Xa inhibitor and may be used in patients with venous thromboembolism (VTE).Objective:To evaluate tolerance, recurrence, bleeding and adverse events in outpatients VTE in treatment with rivaroxaban.Methods: Prospective study from 2011 to 2013. Inclusion criteria: 1) Above 18 years old, 2) Diagnosis of pulmonary embolism (PE) or Deep vein thrombosis (DVT). Exclusion criteria: 1) creatinine clearance < 30 mL / min; 2) Pregnancy. Selected patients were treated according to clinical criteria and/or their preferences about it. An evaluation of tolerance, side effects (bleeding, recurrences and deaths) and adverse events was also carried out.Results: 103 patients were treated with rivaroxaban, with a mean age of 58+/-17 (Mean +/- standard deviation), and 56% male. There was DVT (64.1 %), EP (18.4 %) and DVT + PE (17.5 %). Rivaroxaban was initial treatment in 30% of patients. In 70% rivaroxaban was initiated after low molecular weight heparin (56%) or vitamin K antagonist (43%) whose the median time of anticoagulant previous rivaroxaban was 16 months [range:1-124 months].The median time of rivaroxaban treatment was 5 months. There were no deaths or recurrences. There were 6 bleeding, one mayor (acute hemoperitoneum). We had to withdraw treatment in one patientConclusions: In our study, rivaroxaban efficacy and safety is consistent with the published randomized clinical trials. The convenience of the dosage, the absence of requirements for periodic controls and few interactions with another drugs regarding VKA requires us to consider rivaroxaban in selected group of VTE.